|Bid||35.39 x 100|
|Ask||35.42 x 700|
|Day's range||0.00 - 0.00|
|PE ratio (TTM)||20.22|
|Forward dividend & yield||0.70 (1.95%)|
|1y target est||41.43|
LONDON and NEW YORK , July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence ...
The size of Smith & Nephew plc (LSE:SN.), a UK£11.91B large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averseRead More...
Britain's top share index slipped on Thursday as a tumble in Smith & Nephew's shares and weakness across financials and health stocks dragged the FTSE 100 off a three-month high. Despite a firmer start to trading and a weaker pound, the blue chip FTSE 100 turned lower and ended the session down 0.54 percent at 7,502.69 points, only slightly outperforming a negative European market.
With (Other OTC: WWTH - news) the population ageing in most rich countries round the world, these should in theory be bumper times for Smith & Nephew (Frankfurt: 502816 - news) , Europe's largest maker of artificial knees, shoulders and hips. It's a disappointing last trading update for Olivier Bohuon, who steps down as chief executive on Monday, although in his defence, the Frenchman - a pharmacy graduate - can point out that he has doubled the share price since he took the job in 2011. One is that Smith & Nephew is seeing weakness in a product area for which it is slightly less well-known - advanced wound management, which supplies ointments, bandages and dressings to healthcare suppliers.
U.K. stocks dropped Thursday, following a five-session winning streak for the blue-chip market, with the focus on the U.S. Federal Reserve decision and its flagging of stronger inflation. Stocks were little changed after a reading on British services activity missed expectations. Shares of Smith & Nephew posted the biggest loss in London after a revenue warning.
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
A strong outlook from miner Glencore and gains in oil stocks provided the bedrock for British shares to outperform stock markets on the continent on Thursday. Mining and energy stocks helped the FTSE stay ...
Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker. It also lowered trading profit forecasts, predicting a margin at or above the level achieved last year rather than the 30-70 basis point growth it had targeted. Bohuon, who steps down on Monday, said the business had seen a "mixed performance" in the quarter to end-March, with established markets like the United States and Europe down 2 percent on an underlying basis and emerging markets up 9 percent, resulting in a flat result overall.
Smith & Nephew (Frankfurt: 502816 - news) downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker. It also lowered trading profit forecasts, predicting a margin at or above the level achieved last year rather than the 30-70 basis point growth it had targeted.
European bourses fell in morning trading on Thursday, weighed down by a rebound in the euro and a series of disappointing earning updates including from Smith & Nephew. The pan-European STOXX 600 index ...
** Europe's biggest artificial hip and knee maker slumps 6.1 pct, biggest one-day drop since March 2009 ** Co cuts forecast for 2018 underlying revenue growth and profit margin after some markets softened ...
Smith & Nephew, Europe's biggest artificial hip and knee maker, downgraded its forecast for full-year underlying revenue growth and profit margin after some markets softened and it saw a slowdown in its ...
Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.
Artificial hip and knee maker Smith & Nephew (Frankfurt: 502816 - news) , a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere (NYSE: ALR - news) , where he oversaw its $5.3 billion sale to Abbott in 2017.
Artificial hip and knee maker Smith & Nephew said on Wednesday it had appointed Namal Nawana to replace Olivier Bohuon as chief executive of the British company next month. Nawana was most recently chief ...
The FTSE-100 medical devices group Smith & Nephew (Frankfurt: 502816 - news) (S&N) will this week end its six-month search for a new boss by naming a former Alere (NYSE: ALR - news) executive to the role. Sky News has learnt that S&N will announce on Wednesday that Namal Nawana will join the global leader in orthopaedics reconstruction in the coming months. Mr Nawana, a 46-year-old Australian citizen, will replace Olivier Bohuon, who told the medical technology group's board last October that he intended to step down this year.
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Acclarent received FDA approval for its Acclarent Aera Balloon Dilation System for the treatment of ETD (eustachian tube dysfunction) in September 2016. For details, read Inside Johnson & Johnson’s Latest US Medical Device Launch. On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced that the company received FDA approval for the expanded indication for Acclarent Aera.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
LONDON--(BUSINESSWIRE)-- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of a randomised controlled trial (RCT) demonstrating that the addition ...
Smith & Nephew plc , the global medical technology business, today announces the publication of a randomised controlled trial demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone adhesive foam dressing, to a standard care protocol significantly reduces the onset of pressure ulcers by 71% in elderly patients admitted to hospital for hip fracture1.
Artificial hip and knee maker Smith & Nephew scraped into the bottom of its guidance range for 2017, with a 3 percent rise in revenue to $4.77 billion pounds and a 20 basis point increase in its trading ...
The UK's top share index fell for a third straight day as a deepening global sell-off in the dollar strengthened sterling and dented earnings prospects for British companies exposed to the U.S. currency. ...